99mTc-CNDG SPECT/CT in Brain Tumors
ConditionIntracranial Tumor
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorPeking Union Medical College Hospital
About this trial
The goal of this clinical trial is to evaluate the value of 99mTc-CNDG for diagnosis of brain tumors by comparing it with 18F-FDG-PET. The main questions it aims to answer are:
1. What is the diagnostic consistency between 99mTc-CNDG and 18F-FDG? 2. What is the correlation between the SUVmax value of 99mTc-CNDG and tumor type?
Participants will:
Receive18F-FDG-PET and 99mTc-CNDG examination within 2 weeks before surgery. Obtain pathological diagnosis by surgery or biopsy as the gold standard.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Patients with clinical diagnosis of brain tumor;
Be at least 18 years old;
The final pathological results could be obtained by surgery or biopsy;
Informed consent and the ability to be followed up;
Disqualifiers
Insulin-dependent diabetes mellitus or fasting blood glucose >7 mmol/L before 99mTc-CNDG injection;
Severe liver or kidney disease (serum creatinine level >3.0mg/dL or any liver enzyme level ≥ 5 times the upper limit of normal);
Severe hypersensitivity or hypersensitivity to radiocontrast agents;
Claustrophobia (inability to undergo SPECT/CT or PET/CT scans);
Trial design
Design model
Single group
Treatments tested in this trial
99mTc-CNDG SPECT/CT
Diagnostic testFDG-PET and 99mTc-CNDG will be performed within 2 weeks before surgery.
Treatment groups
30 Participants
are divided into 1 treatment groupGroup A: intracranial tumorExperimental treatment 1 intervention
Trial outcomes
Primary outcomes
1
SUVmax
1\. Diagnostic consistency evaluation of 99mTc-CNDG and 18F-FDG; 2.Correlation of SUV value of 99mTc-CNDGwith tumor type
Time frame
1monthSponsors and contacts
Click on the lead sponsor to view all of their trials.
Source ClinicalTrials.gov